Skip to main content
Clinical Trials/NCT01517633
NCT01517633
Unknown
Phase 2

Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine

Hadassah Medical Organization1 site in 1 country100 target enrollmentJanuary 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Amniotic Fluid Leakage
Sponsor
Hadassah Medical Organization
Enrollment
100
Locations
1
Primary Endpoint
Presence / absence of stains comparing to a known color index printed on the product
Last Updated
14 years ago

Overview

Brief Summary

The purpose of this study is to compare the reliability and validity of a new device with standard methods for diagnosing between amniotic fluid leakage due to premature rupture of the membranes (PROM) and urine.

Detailed Description

Pregnant women sensing wetness and arriving to the delivery room with suspect PROM will use a self-testing device to test whether the wetness is caused by amniotic fluid leakage or urinary incontinence. Clinical evaluation will be performed to all pregnant women using standard clinical tests. The results of the standard clinical tests will be compared to the women's reading of the self-testing device results. Sensitivity and specificity of the device evaluation will be calculated.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
January 2013
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pregnant women age 18 years and older attending delivery room.
  • Stage of gestation: pregnancy between 16 and 42 weeks of gestation.
  • Able and willing to read and sign an informed consent document.

Exclusion Criteria

  • Subjects will be excluded from the study if any of the following will be present:
  • Prior use of any amniotic fluid detection test.
  • Use of vaginal douching apparatus (such as a vaginal bulb syringe) or vaginal products such as creams or gels within the past 24 hours.
  • Vaginal bleeding or spotting or excess abnormal vaginal discharge within the past 24 hours.
  • Sexual intercourse within the past 24 hours.
  • Confirmed diagnosis of any vaginal infection within the past 7 days.
  • Use of vaginal products or antibiotic treatments that reduce bacterial population or use of medications such as tamoxifen that reduce estrogen levels or antihistamines that dry mucous membranes within the past 7 days..
  • Patients unable or unwilling to participate.
  • Patients in active labor (or with regular contractions).

Outcomes

Primary Outcomes

Presence / absence of stains comparing to a known color index printed on the product

Time Frame: 12 hours

Presence / absence of a blue-green stain and / or brown-red stain as yielded by the device and observed by the woman.

Secondary Outcomes

  • Presence / absence of stains comparing to a known color index printed on the product(12 hours)

Study Sites (1)

Loading locations...

Similar Trials